APMA News - November/December 2021 - 74

Teamwork makes
the debridement work
When you combine your sharp debriding skills with the ongoing
debridement power of SANTYL Ointment, you can remove
necrotic tissue at the macroscopic and microscopic levels
without harming healthy granulation tissue. It's all about giving
your patients a clearer path to closure.1
More than half of all patients
pay $10 or less for their
SANTYL Ointment prescriptions.2
Reduction in ulcer area1
from baseline at 6 weeks
36%
Sharp debridement
+ supportive care*
(p=ns)†‡
68%
SANTYL Ointment
+ sharp debridement
+ supportive care*
(p<0.001)†
See the evidence
*Supportive care in the SANTYL Ointment group included ALLEVYN◊
Foam Dressing, cast padding and Coban™
†All patients agreed to wear an offloading boot or other appropriate device.
‡Supportive care in the control group was the clinician's choice.
Important Safety Information
Indications: Collagenase SANTYL Ointment ( " SANTYL " ) is a prescription-only medication indicated for debriding chronic dermal ulcers and severely
burned areas. Contraindications: SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. Warning and
Precautions: The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions
should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used
in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored
for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient
erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. SANTYL is not indicated for
wound closure. Discontinue use of SANTYL after granulation tissue is well-established. Adverse Reactions: No allergic sensitivity or toxic reactions have
been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. For complete prescribing information, please
refer to the accompanying PI or visit: https://santyl.com/sites/default/files/2019-12/SANTYL-PI.pdf. You are encouraged to report negative side effects
of prescription drugs to FDA. Visit MedWatch or call 1-800-FDA-1088.
References: 1. Motley TA, Lange DL, Dickerson JE, Slade HB. Clinical outcomes associated with serial sharp debridement of diabetic foot ulcers with and without clostridial collagenase ointment. Wounds.
2014;26:57-64. 2. IMS Health, Formulary Impact Analyzer. Based on 241,588 retail prescription paid claims, January 2020 through December 2020. Includes copay, coinsurance and paid claims from all
payers (commercial, Medicare, Medicaid, and cash pay.
Advanced Wound Management. Smith+Nephew, Inc. ◊
Trademark of Smith+Nephew. © 2021 Smith+Nephew. Learn more at www.santyl.com | SAEE129-27262-1021
bandages.

https://www.santyl.com/sites/default/files/2019-12/SANTYL-PI.pdf http://www.santyl.com

APMA News - November/December 2021

Table of Contents for the Digital Edition of APMA News - November/December 2021